BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 26048120)

  • 1. [Not Available].
    Wolf E; Rüsenberg R
    MMW Fortschr Med; 2015 Jun; 157 Suppl 2():42-5. PubMed ID: 26048120
    [No Abstract]   [Full Text] [Related]  

  • 2. [Not Available].
    Stingl W
    MMW Fortschr Med; 2015 Jun; 157 Suppl 2():55. PubMed ID: 26048126
    [No Abstract]   [Full Text] [Related]  

  • 3. [Declining costs].
    Neumaier J
    MMW Fortschr Med; 2016 Jun; 158 Suppl 1():58. PubMed ID: 27259908
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
    Saab S; Gordon SC; Park H; Sulkowski M; Ahmed A; Younossi Z
    Aliment Pharmacol Ther; 2014 Sep; 40(6):657-75. PubMed ID: 25065960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [HIV infection and AIDS from the health policy viewpoint. Savings and therapy superiority maintained - a contradiction in HIV therapy?].
    MMW Fortschr Med; 2014 Jun; 156 Suppl 1():62-3. PubMed ID: 25026863
    [No Abstract]   [Full Text] [Related]  

  • 6. Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial.
    Stahmeyer JT; Krauth C; Bert F; Pfeiffer-Vornkahl H; Alshuth U; Hüppe D; Mauss S; Rossol S
    J Viral Hepat; 2016 Feb; 23(2):105-15. PubMed ID: 26411532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Does combination therapy of chronic viral hepatitis C with interferon-alpha and ribavirin approach financial limits?].
    Steimann RU; Bode JC
    Versicherungsmedizin; 2000 Mar; 52(1):24-7. PubMed ID: 10718088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost of treating hepatitis C in Germany: a retrospective multicenter analysis.
    Stahmeyer JT; Rossol S; Bert F; Antoni C; Demir M; Hinrichsen H; Hüppe D; Teuber G; Wiebner B; Wedemeyer H; Krauth C
    Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1278-85. PubMed ID: 25144493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012].
    Blasco AJ; Arribas JR; Boix V; Clotet B; Domingo P; González-García J; Knobel H; López JC; Llibre JM; Lozano F; Miró JM; Podzamczer D; Santamaría JM; Tuset M; Zamora L; Lázaro P; Gatell JM;
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):283-93. PubMed ID: 22525829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost of antiretroviral treatment for HIV patients in two centres of North India.
    Sharma A; Prinja S; Sharma A; Gupta A; Arora SK
    Int J STD AIDS; 2019 Jul; 30(8):769-778. PubMed ID: 31081489
    [No Abstract]   [Full Text] [Related]  

  • 11. Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C.
    Gellad ZF; Reed SD; Muir AJ
    Antivir Ther; 2012; 17(6 Pt B):1189-99. PubMed ID: 23186646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The cost of an HIV patient. Lack of funds for optimal treatment?].
    Stoll M; Schulte E; Claes C; Graf von der Schulenburg JM; Schmidt RE
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():72-7. PubMed ID: 11373789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Special report: cost-effectiveness studies of new hepatitis C treatments.
    Mark DH;
    Technol Eval Cent Assess Program Exec Summ; 2015 Jan; 29(10):1-3. PubMed ID: 25962188
    [No Abstract]   [Full Text] [Related]  

  • 14. [Costs of a guideline-based treatment of patients with chronic hepatitis C in the era of interferon-free treatment].
    Stahmeyer JT; Rossol S; Bert F; Liersch S; Krauth C
    Z Gastroenterol; 2016 Aug; 54(8):760-9. PubMed ID: 27529526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs of eliminating HIV in South Africa have been underestimated.
    Wagner B; Blower S
    Lancet; 2010 Sep; 376(9745):953-4. PubMed ID: 20851250
    [No Abstract]   [Full Text] [Related]  

  • 16. [Costs of a guideline-based treatment of patients with chronic hepatitis C in Germany].
    Stahmeyer JT; Rossol S; Bert F; Abdelfattah M; Krauth C
    Z Gastroenterol; 2014 Sep; 52(9):1041-9. PubMed ID: 25075995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.
    Zhao YJ; Khoo AL; Lin L; Teng M; Koh CJ; Lim SG; Lim BP; Dan YY
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1628-37. PubMed ID: 26990023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia.
    Poordad F; Theodore D; Sullivan J; Grotzinger K
    J Med Econ; 2011; 14(2):194-206. PubMed ID: 21348807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Naturopathy consultation. Soon all patients will be curable. Decisive breakthrough in therapy of hepatitis C ].
    Einecke D
    MMW Fortschr Med; 2014 Feb; 156(3):26-7. PubMed ID: 24938054
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.